BioSpace News Archive

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data presentations of four toripalimab pivotal clinical studies will be presented at the upcoming ASCO Annual Meeting, which is being held from June 2-6, 2023 at McCormick Place in Chicago.

Therini Bio, Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today announced the close of a $36M Series A financing round.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announced that it plans to release its unaudited financial results for the first quarter of 2023 before the U.S. market opens on May 30, 2023.

Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the first quarter of 2023.

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announces the following activities in May.

NeoDynamics, Inc. announced the U.S. availability of NEONAVIA, the first and only biopsy system built on a patented pulse technology for controlled and precise needle insertion.

Arbutus Biopharma Corporation announced that clinical data for AB-729, an RNAi therapeutic, and preclinical data for AB-161, a next-generation oral HBV specific RNA destabilizer, were presented as late-breaker oral presentations at the Global Hepatitis Summit 2023 in Paris.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy annual meeting being held on May 3-5, 2023, in Mainz.

ITM Isotope Technologies Munich SE announced that it has entered into a co-development and exclusive license agreement with the Paul Scherrer Institute, a leading Swiss research institute in the natural and engineering sciences, for the implementation of upscaled manufacturing of a novel therapeutic radionuclide, terbium-161.

Bionomics Limited announced that the Company has completed target enrollment of approximately 200 participants in its randomized, double-blind, placebo-controlled, multi-center Phase 2b ATTUNE clinical trial evaluating BNC210 in Post-Traumatic Stress Disorder.